title: Successful alectinib treatment after crizotinib-induced interstitial lung disease.
abstract: A 70-year-old woman with lung adenocarcinoma, harbouring anaplastic lymphoma kinase gene rearrangement, was treated with crizotinib as third-line chemotherapy. After 2 months, crizotinib was discontinued because of the development of crizotinib-induced interstitial lung disease (ILD). Steroid treatment was then introduced and tapered off. Following complete resolution of the interstitial shadow, cytotoxic chemotherapy was initiated, and continued for over 2 years, until new intrapulmonary lesions developed. Although there was a risk of drug-induced interstitial pneumonia, alectinib was initiated as the fifth-line therapy, without steroid supplementation, as there was no alternative treatment. No recurrence of ILD was noted at 10 months. To our knowledge, this is the first report of successful alectinib treatment after the development of crizotinib-induced ILD without the use of prednisolone.
authors: Department of Respiratory Medicine National Hospital Organization, Asahikawa Medical Center 7 Hanasaki Asahikawa Japan.
authors: Satoru
authors: S
authors: Fujiuchi
authors: Department of Respiratory Medicine National Hospital Organization, Asahikawa Medical Center 7 Hanasaki Asahikawa Japan.
authors: Yuka
authors: Y
authors: Fujita
authors: Respiratory Center Asahikawa Medical University 2-1-1-1 Midorigaoka Higashi Asahikawa Japan.
authors: Takaaki
authors: T
authors: Sasaki
authors: Respiratory Center Asahikawa Medical University 2-1-1-1 Midorigaoka Higashi Asahikawa Japan.
authors: Yoshinobu
authors: Y
authors: Ohsaki
keywords: anaplastic lymphoma kinase‐tyrosine kinase inhibitor; interstitial lung disease